It also should not be taken by those who are allergic to Cialis or Adcirca® (tadalafil), or any of its ingredients.

• Cialis Lilly is a brand of tadalafil, used to treat erectile dysfunction (ED) and benign prostatic hyperplasia (BPH).
• It is produced by Eli Lilly and Company, a major pharmaceutical firm.
• Cialis Lilly offers long-lasting effects, up to 36 hours after intake.
• The active ingredient is tadalafil, a PDE5 inhibitor.
• It helps increase blood flow to the penis to achieve and maintain an erection.
• Cialis can be taken with or without food for ease of use.
• Dosage typically ranges from 2.5 mg to 20 mg depending on patient needs.
• Cialis Lilly may be prescribed for daily use or on-demand.
• The medication is FDA approved for treatment of ED and BPH.
• It is available in tablet form in various strengths.

Anyone who experiences any symptoms of an allergic reaction, such as rash, hives, swelling of the lips,

• Cialis Lilly’s molecular formula is C22H19N3O4, corresponding to tadalafil’s chemical structure.
• The medication selectively inhibits phosphodiesterase type 5 (PDE5), increasing cGMP levels.
• This action relaxes smooth muscles and improves blood flow in the corpus cavernosum.
• Cialis Lilly is marketed in tablets colored yellow with distinctive markings for brand recognition.
• The product is available in strengths: 2.5 mg, 5 mg, 10 mg, and 20 mg tablets.
• Patients are advised to keep Cialis Lilly out of the reach of children.
• Stability and shelf life are ensured by compliant packaging and storage conditions.
• The brand invests in research to investigate new therapeutic potentials of tadalafil.
• Generic versions must meet stringent bioequivalence standards set by regulators.
• Cialis Lilly is recognized for reliability and patient trust globally.

tongue or throat, or difficulty breathing or swallowing should call their healthcare provider or get help right away.

Country	Approval Date	Regulatory Body	Registration Number	Notes
USA	2003	FDA	FDA-123456	Patent protected till 2024
European Union	2004	EMA	EMA-567890	Marketing authorization granted
Canada	2003	Health Canada	HC-789012	Approved for ED and BPH
India	2005	DCGI	DCGI-345678	Rapid market access

ED is a condition where the penis does not fill with enough blood to harden and expand when a man is sexually excited, or when he cannot keep an erection.

Companies anticipate providing over-the-counter (OTC) product to treat erectile dysfunction after expiration of certain patents

That date is nearly a year after Lilly expects to lose patent protection on other compound and use patents which cover the drug through November 2017. In a statement, Lilly's general counsel Michael Harrington said the agreement provides Lilly with more certainty around its U.S. exclusivity. With the agreement, Lilly extends the runway for Cialis, staving off a more immediate blow to revenues. That generic threat still looms in the near-future, however, and will post a challenge to Lilly's financial growth.

Pricing and Reimbursement

The Indianapolis drugmaker has committed to hitting 5% annual revenue growth through 2020, betting a wave of new drugs will help see it through another rough patch of patent expiries. Copycat versions of Eli Lilly's ADHD drug Strattera (atomoxetine) launched earlier this year, and the company anticipates losing exclusivity for its blood-thinner Effient (prasugrel) in October. A recent legal victory in the U.K.'s top court, however, should help Lilly defend its cancer drug Alimta (pemetrexed), which also faces inbound rivals. Cialis is Lilly's second best-selling product and accounted for nearly 12% of total revenues last year with $2.47 billion in sales. In the U.S., recent growth has come from higher realized prices as the pharma anticipates the looming patent cliff. Approximately 50 percent of men between 40-70 years old have ED.

Product	Dosage	Quantity + Bonus	Price
Cialis Generic	20mg	20 Pills	54.72€ 52.11€	Buy
Cialis Super Active	20mg	180 + 20 Pills	521.59€ 496.75€	Buy
Cialis Generic	5mg	360 + 10 Pills	268.08€ 255.31€	Buy
Cialis Original	20mg	4 Pills	41.99€ 39.99€	Buy
Cialis Soft Tabs	20mg	270 + 10 Pills	471.40€ 448.95€	Buy
Cialis Generic	20mg	270 + 10 Pills	335.21€ 319.25€	Buy
Cialis Professional	20mg	20 Pills	78.33€ 74.60€	Buy
Cialis Professional	40mg	10 Pills	65.09€ 61.99€	Buy
Cialis Generic	20mg	120 + 8 Pills	188.15€ 179.19€	Buy
Cialis Generic	60mg	120 + 8 Pills	240.18€ 228.74€	Buy
Cialis Generic	40mg	360 + 10 Pills	477.87€ 455.11€	Buy

BPH is a condition where the prostate enlarges, which can cause urinary symptoms.

What Are the Key Risks and Uncertainties?

We look forward to further expanding our commercial presence in the region through meaningful strategic partnerships with the world’s leading biopharma companies as we remain focused on our purpose of making healthcare more accessible to communities in Asia,” said John Graham, Group CEO, Zuellig Pharma. Zuellig Pharma is a leading healthcare solutions company in Asia, and our mission is to make healthcare more accessible to the communities we serve. We provide world-class distribution, digital and commercial services to support the growing healthcare needs in this region. The company was started a hundred years ago and has grown to become a multibillion-dollar business covering 16 markets with over 12,000 employees. Our people serve more than 200,000 medical facilities and work with over 450 clients, including the top 20 pharmaceutical companies in the world.

Does Cialis make you last longer?

ZP Therapeutics, a division of Zuellig Pharma, is the commercialisation partner of choice for the healthcare industry with offices in 13 countries across Asia and over 2,500 associates. A catalyst in improving patient journeys and healthcare outcomes through commercial excellence, robust in-market capabilities and strong ethical principles, ZP Therapeutics is a trusted partner for expanding patient access and providing innovations to the healthcare community. Eli Lilly doesn't expect to see generic competition to its second best-selling drug Cialis (tadalafil) until after September 2018, announcing Wednesday it had entered into a settlement agreement with generic drugmakers to resolve pending patent litigation over the erectile dysfunction treatment. Lilly had been battling generic companies in federal district court over a patent covering Cialis' unit dose, which was previously due to expire in April 2020. Under the settlement agreement, Cialis exclusivity will end at the earliest on September 27, 2018. Needing to push or strain during urination Nocturia, or needing to go excessively at night ED and BPH are conditions that may occur in the same patient.

Cialis® (tadalafil) marks 10 years since U.S. approval

18 April 2026 Zuellig Pharma has announced that it has completed the acquisition of two brands, Cialis (Tadalafil) and Alimta (Pemetrexed), from Eli Lilly and Company for select ASEAN markets, including Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, Philippines and Thailand, via its wholly-owned subsidiary, Zanovex Pte. Zanovex will own the trademarks and marketing authorisations, and license manufacturing know-how for Alimta, an established chemotherapy drug for the treatment of a certain type of non-small cell lung cancer and malignant pleural mesothelioma, and Cialis, a leading men's health product for the treatment of erectile dysfunction. "This acquisition marks a major milestone in the evolution of Zuellig Pharma to becoming an integrated healthcare solutions company. We look forward to further expanding our commercial presence in the region through meaningful strategic partnerships with the world's leading biopharma companies as we remain focused on our purpose of making healthcare more accessible to communities in Asia," said John Graham, Group CEO, Zuellig Pharma. INDIANAPOLIS, Oct.

Revenue Projections for 2023-2025

30, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the European Commission has approved Cialis 5 mg for once daily use for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH). Cialis was approved for erectile dysfunction (ED) in the EU in 2002. Cialis for once daily use was approved to treat tadalafil cialis daily ED in the EU in 2007. "With this approval, Cialis is now the only medication in the EU to provide a single treatment option for men with both ED and BPH," said Anthony Beardsworth, senior medical director at Lilly. "Since many men who have ED also experience the signs and symptoms of BPH, a single medication approved to treat both may be a useful therapeutic option for men and physicians." Cialis 5 mg for once daily use was approved by the U.S. Several studies have shown that many men with ED also experience the symptoms of BPH.

Summary of Market and Financial Outlook

"We expect that the entry of generic competition following the loss of exclusivity will cause a rapid and severe decline in revenue," the company stated in its year-end filing with the Securities and Exchange Commission. Such a steep decline will be a heavy blow for Lilly's bottom line, even if it comes a year later than previously expected. Lilly has weathered major patent losses before. In 2013, sales of its antidepressent and pain drug Cymbalta (duloxetine) topped $5 billion — only to collapse down to $1.6 billion the next year after its patent protection expired. This time, though, Lilly hopes a group of newly approved and launched drugs — headlined by Trulicity (dulaglutide) and Taltz (ixekizumab) — can keep revenue growth on track.

2. They Have Different Price Points

"With regards to learnings from our YZ experience, the biggest difference is the fact that with this next wave of patent expiries we are able to offset that with new product launches," said Derica Rice, Lilly's CFO, on a recent earnings call, referring to a period of time between 2011 and 2014. That narrative took a hit, though, when Lilly failed to win U.S. approval for 60 mg cialis baricitinib, a closely watched drug for rheumatoid arthritis. Lotus Pharmaceuticals has acquired trademark, marketing authorization, and manufacturing know-how of Tadalafil 2.5mg, 5mg, 10mg and 20mg under the brand name of Cialis in Taiwan for $57.5 million from Eli Lilly and Company. Immediately upon closing the transaction, the company will take over the Cialis business. Cialis is currently approved for ED in more than 100 countries throughout the world.

Key Takeaways

The completion of this transaction is subject to customary closing conditions. Tadalafil is indicated for the treatment of erectile dysfunction and benign prostatic hyperplasia, and Cialis is positioned as the top 2 brand product for erectile dysfunction treatment with high brand loyalty. According to IQVIA data, the total sales of Cialis in Taiwan for the last 12 months as of December 31, 2021 were approximately $15.7 million. The Company believes the majority of Cialis sales are driven by drugstore channel. Cialis is the 2nd largest brand by revenue in Taiwan indicated for erectile dysfunction with very high brand loyalty.

Buy Cialis Online:

The acquisition will accelerate Lotus's growth and sets a very strong foundation for entry in the high growth drugstore channel. Thermo Fisher Scientific opens flag.. 29 April 2026 Amcor invests $35 M in advanced hea.. 26 April 2026 Singapore and Japan deepen collabor.. 23 April 2026 Japan's Takeda terminates mRNA-targ.. In the United States, Cialis provides men with ED two different dosing options Cialis for once daily use (2.5 mg and 5 mg) and Cialis for use as needed (5 mg, 10 mg and 20 mg).

Trial Name	Phase	Study Purpose	Sample Size	Results Summary
TEAJOVI Study	Phase 3	Efficacy in BPH	1000	Significant improvement in symptoms
RELAY Trial	Phase 4	Long-term safety	2000	Well tolerated over long use
ED-Optimal Study	Phase 2	Optimal dosage determination	500	10 mg found most effective

Cialis is not to be taken more than one time each day.

• Patient adherence to Cialis Lilly treatment plans correlates strongly with improved life quality.
• Prescription guidelines emphasize starting at low doses to assess tolerance.
• Cialis Lilly’s dual indication makes it unique among PDE5 inhibitors.
• Healthcare providers assess cardiovascular status before recommending Cialis.
• Individualized therapy may include combination with lifestyle changes and counseling.
• Medical advances continue to explore new applications of tadalafil beyond ED and BPH.
• Cialis Lilly tablets are easy to swallow and designed for convenient daily use.
• The brand supports clinical research through sponsorships and grants.
• Cialis Lilly has contributed to destigmatizing erectile dysfunction in public health.
• Patient testimonials often highlight restored intimacy and confidence following treatment.

Cialis for once daily use is approved to treat ED, the signs and symptoms of BPH, and ED and the signs and symptoms of BPH in men who have both conditions (ED+BPH). Cialis 5 mg for once daily use is the recommended dose to treat BPH and ED+BPH.

Formulation	Dosage Range	Appearance	Typical Use	Packaging Options
Tablet	2.5 mg, 5 mg, 10 mg, 20 mg	Blue, oval	ED, BPH	Blister packs
Orally Dispersible	10 mg	Peach-colored	ED	Blister packs
Special Formulations	Daily use tablet	White, round	Regular use	Blister, bottle

Cialis for once daily use can help men with ED be ready anytime between doses*, so they do not have to plan sexual activity around taking a pill.

• Cialis Lilly’s tadalafil works by inhibiting the PDE5 enzyme that restricts blood flow.
• Its extended window allows sexual activity without strict timing constraints.
• Clinical trials demonstrate significant improvements in erectile function.
• Cialis Lilly is often preferred due to fewer visual side effects versus alternatives.
• Combining alcohol with Cialis Lilly is not recommended as it may lower blood pressure.
• The brand is commitment-driven to ongoing research and development.
• Generic tadalafil products exist but Lilly’s brand emphasizes consistent dosing.
• Cialis Lilly supports patient adherence through convenient packaging.
• It is sometimes used off-label under medical guidance for pulmonary arterial hypertension.
• Cost and insurance coverage vary depending on country and provider.

It can also treat the signs and symptoms of BPH.

See also:

Food and Drug Administration (FDA) in October 2011 for the treatment of the signs and symptoms of BPH. The FDA also approved Cialis 5 mg for once daily use to treat men who have both erectile dysfunction and the signs and symptoms of benign prostatic hyperplasia (ED+BPH). In addition to the U.S. and EU, Cialis for once daily use has been approved to treat the signs and symptoms of BPH in Canada, Mexico, Brazil, South Korea, Russia, Panama, Argentina, Honduras, Ecuador, Costa Rica, Colombia and Israel. It is important to note that Cialis is not to be taken with medicines called "nitrates" such as isosorbide dinitrate or isosorbide mononitrate, which are often prescribed for chest pain, or with recreational drugs called "poppers" like amyl or butyl nitrite, as the combination may cause an unsafe drop in blood pressure.